Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Scavenger receptor class A (SR-A, MSR1) and scavenger receptor class B member 1 (SR-B1, SCARB1) are key membrane glycoproteins expressed on macrophages that play critical, yet distinct, roles in lipid metabolism and innate immunity [1, 6, 7]. SR-A is primarily responsible for the endocytic uptake of modified low-density lipoproteins (LDL), such as oxidized or acetylated LDL, which contributes to the formation of lipid-laden foam cells in atherosclerotic plaques [7]. In contrast, SR-B1 serves as a high-affinity receptor for high-density lipoprotein (HDL), mediating the selective uptake of cholesteryl esters and facilitating the efflux of free cholesterol, thereby supporting reverse cholesterol transport and exerting atheroprotective effects [1, 4, 6]. Beyond lipid trafficking, both receptors participate in the immune response; SR-A recognizes a wide array of polyanionic ligands including bacterial components, while SR-B1 is involved in the phagocytosis of apoptotic cells (efferocytosis) and serves as a co-receptor for certain viruses like Hepatitis C [1, 4, 7, 8]. Therapeutic targeting of these receptors is being explored for cardiovascular disease, where SR-B1 activation or SR-A inhibition might reduce plaque progression, and in oncology, where SR-B1 overexpression in certain tumors is leveraged for targeted drug delivery using reconstituted HDL nanoparticles [5, 10, 12]. However, pharmacological modulation faces challenges, such as the potential for SR-B1 inhibition to impair steroidogenesis in the adrenal glands or SR-A deficiency to compromise host defense against infections [1, 4, 7].
SR-B1 mediates the selective uptake of cholesteryl esters from HDL and bidirectional flux of free cholesterol between cells and lipoproteins [1, 4], while SR-A mediates the endocytosis of modified low-density lipoproteins (LDL) and the recognition of various polyanionic ligands including bacterial components [7].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Scavenger receptor class A and Scavenger receptor class B member 1 (SR-A/SR-B1).